Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Non Operating Income (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Non Operating Income data on record, last reported at -$125000.0 in Q4 2025.

  • For Q4 2025, Non Operating Income fell 100.88% year-over-year to -$125000.0; the TTM value through Dec 2025 reached -$357000.0, down 100.74%, while the annual FY2025 figure was -$357000.0, 100.87% down from the prior year.
  • Non Operating Income reached -$125000.0 in Q4 2025 per CRNX's latest filing, up from -$14.9 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $27.0 million in Q3 2024 and bottomed at -$14.9 million in Q3 2025.
  • Average Non Operating Income over 5 years is $3.4 million, with a median of $1.1 million recorded in 2022.
  • Peak YoY movement for Non Operating Income: crashed 855.56% in 2021, then skyrocketed 2829.24% in 2022.
  • A 5-year view of Non Operating Income shows it stood at $171000.0 in 2021, then surged by 2829.24% to $5.0 million in 2022, then soared by 35.0% to $6.8 million in 2023, then soared by 109.26% to $14.2 million in 2024, then plummeted by 100.88% to -$125000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were -$125000.0 in Q4 2025, -$14.9 million in Q3 2025, and $20000.0 in Q2 2025.